RXRX Stock Chart & Stats
$59.39
$0.00(0.00%)
At close: 4:00 PM EDT
$59.39
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$49.00 - $130.00
Previous CloseN/A
Volume0.00
Average Volume (3M)1.10K
Market Cap
$29.30B
Enterprise Value$1.47K
Total Cash (Recent Filing)$545.68M
Total Debt (Recent Filing)$61.88M
Price to Earnings (P/E)―
Beta-0.20
Next Earnings
Nov 11, 2026EPS Estimate
-3.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares OutstandingN/A
10 Day Avg. Volume3,066
30 Day Avg. Volume1,100
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.62
Price to Sales (P/S)24.50
P/FCF Ratio-4.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$108.72Price Target Upside83.06% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-15.11
Revenue Forecast (FY)$858.46M
Bulls Say, Bears Say
Bulls Say
AI Platform EfficiencyLarge proprietary datasets plus reported design speed and compound savings can support a repeatable discovery advantage. If these workflows continue to translate into faster candidate selection and better trial execution, Recursion may scale programs and partner output more efficiently than conventional approaches.
Partnership Cash GenerationMeaningful realized partner payments validate external demand for Recursion’s platform and provide non-dilutive funding for internal development. Additional milestone opportunities and potential royalties could extend the platform’s economic value beyond current collaboration receipts if programs advance.
Pipeline AdvancementA growing clinical portfolio creates multiple potential value drivers rather than reliance on one candidate. REC-4881’s early efficacy signal and REC-7735’s cleared IND demonstrate progression from platform discovery toward human testing, improving the company’s long-term development prospects.
Bears Say
Persistent Losses And Cash BurnHeavy cash consumption and declining trailing revenue show that the current business is not self-funding. Persistent development spending without offsetting product revenue can erode financial resources and increase dependence on partnerships, milestones, or future capital to sustain the pipeline.
Clinical And Regulatory UncertaintyEncouraging early data do not yet establish durable benefit or a registrational path. Pending efficacy, safety, endpoint, and regulatory validation leave substantial execution risk, and setbacks in a lead program could reduce the expected value of the broader development portfolio.
Runway Timing RiskEven after cost reductions, the timing of clinical readouts may not align with available liquidity. If milestones are delayed or partnership receipts do not arrive as planned, Recursion could need additional funding, potentially constraining strategy or diluting existing shareholders.
Recursion Pharmaceuticals News
RXRX FAQ
What was Recursion Pharmaceuticals’s price range in the past 12 months?
Recursion Pharmaceuticals lowest stock price was $49.00 and its highest was $130.00 in the past 12 months.
What is Recursion Pharmaceuticals’s market cap?
Recursion Pharmaceuticals’s market cap is $29.30B.
When is Recursion Pharmaceuticals’s upcoming earnings report date?
Recursion Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 61 days.
How were Recursion Pharmaceuticals’s earnings last quarter?
Recursion Pharmaceuticals released its earnings results on Aug 05, 2026. The company reported -$4.252 earnings per share for the quarter, missing the consensus estimate of -$4.082 by -$0.17.
Is Recursion Pharmaceuticals overvalued?
According to Wall Street analysts Recursion Pharmaceuticals’s price is currently Undervalued.
Does Recursion Pharmaceuticals pay dividends?
Recursion Pharmaceuticals does not currently pay dividends.
What is Recursion Pharmaceuticals’s EPS estimate?
Recursion Pharmaceuticals’s EPS estimate is -3.72.
How many shares outstanding does Recursion Pharmaceuticals have?
Currently, no data Available
What happened to Recursion Pharmaceuticals’s price movement after its last earnings report?
Recursion Pharmaceuticals reported an EPS of -$4.252 in its last earnings report, missing expectations of -$4.082. Following the earnings report the stock price went down -0.054%.
Which hedge fund is a major shareholder of Recursion Pharmaceuticals?
Currently, no hedge funds are holding shares in MX:RXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Recursion Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$108.72 (83.06% Upside)
$108.72 (83.06% Upside)
Blogger Sentiment
Neutral
MX:RXRX Sentiment 50%
Sector Average 61%
Sector Average 61%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
RXRX Company Deck
RXRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a strong set of operational and technical highlights: multiple advancing clinical programs with compelling early efficacy (REC-4881), a cleared IND for a precision-selective oncology candidate (REC-7735), large proprietary data assets (>50 PB, massive cellular atlases), meaningful partnership cash inflows (> $500M realized, > $260M from Roche-Genentech) and demonstrated efficiency gains in design speed and operating costs (guidance lowered to $375M, ~40% reduction vs 2024 pro forma). Key risks and lowlights are typical for a clinical-stage biotech: regulatory and clinical uncertainty in rare disease and CNS programs, timing of pivotal data (some milestones extend beyond the current cash runway), competitive pressure as AI tools proliferate, and the early-stage nature of some proofs. Overall, positive operational momentum and external validation from partners outweigh the remaining clinical and market risks, but the company still faces execution and timing risks as programs advance.View all MX:RXRX earnings summariesRXRX Stock 12 Month Forecast
Average Price Target
$108.72
▲(83.06% Upside)